	US 11,912,746 B2
	PD-1 homing endonuclease variants, compositions, and methods of use
Jasdeep Mann, Seattle, WA (US); Joel Gay, Seattle, WA (US); Jordan Jarjour, Seattle, WA (US); and Joy Zhang, Seattle, WA (US)
Assigned to 2seventy bio, Inc., Cambridge, MA (US)
Filed by 2seventy bio, Inc., Cambridge, MA (US)
Filed on May 6, 2022, as Appl. No. 17/738,484.
Application 17/738,484 is a continuation of application No. 16/330,039, granted, now 11,365,226, previously published as PCT/US2017/050774, filed on Sep. 8, 2017.
Claims priority of provisional application 62/414,279, filed on Oct. 28, 2016.
Claims priority of provisional application 62/385,079, filed on Sep. 8, 2016.
Prior Publication US 2022/0340626 A1, Oct. 27, 2022
Int. Cl. C07K 14/47 (2006.01); C12N 15/86 (2006.01)

CPC C07K 14/4702 (2013.01) [C12N 15/86 (2013.01); C07K 2319/80 (2013.01)]

16 Claims

1. A method of editing a human PD-1 gene in a cell comprising: introducing a polynucleotide encoding a polypeptide into the cell,

wherein the polypeptide comprises an I-OnuI homing endonuclease (HE) variant comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 61, and that binds and cleaves the target polynucleotide sequence in the human program cell death 1 (PD-1) gene set forth in SEQ ID NO: 30;

wherein expression of the polypeptide creates a double strand break at a target site in a human PD-1 gene; and

wherein the cell is a hematopoietic cell.